CytoSorbents to Report Third Quarter Fiscal 2013 Operating and Financial Results

CytoSorbents to Report Third Quarter Fiscal 2013 Operating and Financial Results 
MONMOUTH JUNCTION, NJ -- (Marketwired) -- 10/22/13 --  CytoSorbents
Corporation (OTCQB: CTSO), a critical care focused company
commercializing its European Union approved CytoSorb(R) blood filter
to treat life-threatening illnesses in the intensive care unit, will
report Q3 2013 earnings after the market close on Wednesday, November
6, 2013.  
CytoSorbents management will also host a live conference call and
presentation webcast that will recount both operational and financial
progress during the quarter.  
Conference Call Details:
 Date: Wednesday, November 6, 2013 
4:15 p.m. Eastern
 Participant Dial-In: (480) 629-9665
Presentation Webcast: 
It is recommended that participants dial in approximately 10 minutes
prior to the start of the call. There will also be a simultaneous
live webcast of the conference call that can be accessed through the
following audio feed link: 
An archived recording of the conference call will be available under
the Investor Relations section of the Company's website at 
Investors are encouraged to submit their questions in advance as soon
as possible to Mr. Valter Pinto of Alliance Advisors at 
About CytoSorbents Corporation  
CytoSorbents is a critical care focused therapeutics company using
blood purification to control severe inflammation -- with the goal of
preventing or treating multiple organ failure caused by uncontrolled
inflammation in life-threatening illnesses. Organ failure is the
cause of nearly half of all deaths in the intensive care unit, with
little to improve clinical outcome. CytoSorb(R), the Company's
flagship product, is approved in the European Union as a safe and
effective extracorporeal cytokine filter, designed to reduce the
"cytokine storm" that could otherwise cause massive inflammation,
organ failure and death in common critical illnesses such as sepsis,
burn injury, trauma, lung injury, and pancreatitis. These are
conditions where the mortality is extremely high, yet no effective
treatments exist. CytoSorbents' purification technologies are based
on biocompatible, highly porous polymer beads that can actively
remove toxic substances from blood and other bodily fluids by pore
capture and surface adsorption. CytoSorbents has numerous products
under development based upon this unique blood purification
technology, protected by 32 issued US patents and multiple
applications pending, including HemoDefend(TM), ContrastSorb,
DrugSorb, and others. Additional information is available for
download on the Company's website: 
Forward-Looking Statements
 This press release includes
forward-looking statements intended to qualify for the safe harbor
from liability established by the Private Securities Litigation
Reform Act of 1995. Forward-looking statements in this press release
are not promises or guarantees and are subject to risks and
uncertainties that could cause our actual results to differ
materially from those anticipated. These statements are based on
management's current expectations and assumptions and are naturally
subject to uncertainty and changes in circumstances. We caution you
not to place undue reliance upon any such forward-looking statements.
Actual results may differ materially from those expressed or implied
by the statements herein. Risk factors are detailed in the Company's
Form 10-K filed with the SEC on April 3, 2013, which is available at 
Company Contact:
CytoSorbents Corporation
Dr. Phillip Chan
Chief Executive Officer
(732) 329-8885 ext. *823 
Investor Contact:
Alliance Advisors, LLC
Alan Sheinwald
(914) 669-0222 
Valter Pinto
(914) 669-0222 x201 
Media Contact:
JQA Partners
Jules Abraham
(917) 885-7378 
Press spacebar to pause and continue. Press esc to stop.